Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOPPLER: Upadacitinib MTX Discontinuation in RA
NCT05121298Phase 3Unknown
- Sponsor
- Atsushi Kawakami
- Start
- Jan 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of upadacitinib in rheumatoid arthritis (RA), sponsored by Atsushi Kawakami. Primary endpoint: Maintenance of DAS28-CRP <= 3.2 at 48 weeks. Status: unknown.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05121298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121298.